A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer
To demonstrate the efficacy of cyclotron-produced Tc-99m pertechnetate (C-PERT; manufactured
by the Edmonton PET Centre/ERC) in comparison to generator-produced Tc-99m pertechnetate
(G-PERT; from approved commercial source; using qualitative and quantitative clinical
imaging biodistribution data.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
To demonstrate the efficacy of C-PERT (manufactured by the Edmonton PET Centre/ERC) in comparison to G-PERT (fromm approved commercial sources) using qualitative and quantitative clinical imaging biodistribtion data.
AJB McEwan, MB
Department of Oncology, Cross Cancer Institute, Cancer Care, Alberta Health Services
Canada: Health Canada